Dr. rer. nat. Miriam Heinig

• Krebsepidemiologie
• Krebsfrüherkennung
• Krebsprävention
• Brustkrebs
• Postmenopausale Hormontherapie
• Sekundärdaten

• Evaluation der Brustkrebsmortalität im deutschen Mammographie- Screening-Programm- 2. Teil der Hauptstudie

Ausgewählte BIPS-Veröffentlichungen

• Zeitschriftenartikel mit peer-review

• Damm M, Heinig M, Rosendahl J, Michl P, Haug U, Krug S. Trends in the treatment and survival of pancreatic cancer: Analysis of 23,339 patients diagnosed between 2010 and 2017. Cancer Medicine. 2025;14(18):e71248.
  https://doi.org/10.1002/cam4.71248
• Heinig M, Schäfer W, Langner I, Zeeb H, Haug U. German mammography screening program: Adherence, characteristics of (non-)participants and utilization of non-screening mammography - A longitudinal analysis. BMC Public Health. 2023;23:1678.
  https://doi.org/10.1186/s12889-023-16589-5
• Heinze F, Czwikla J, Heinig M, Langner I, Haug U. German mammography screening program: Program sensitivity between 2010 and 2016 estimated based on German health claims data. BMC Cancer. 2023;23:852.
  https://doi.org/10.1186/s12885-023-11378-0
• Braitmaier M, Kollhorst B, Heinig M, Langner I, Czwikla J, Heinze F, Buschmann L, Minnerup H, García-Albéniz X, Hense H-W, Karch A, Zeeb H, Haug U, Didelez V. Effectiveness of mammography screening on breast cancer mortality - A study protocol for emulation of target trials using German health claims data. Clinical Epidemiology. 2022;14:1293-1303.
  https://doi.org/10.2147/CLEP.S376107
• Heinig M, Heinze F, Schwarz S, Haug U. Initial and ten-year treatment patterns among 11,000 breast cancer patients undergoing breast surgery - An analysis of German claims data. BMC Cancer. 2022;22:130.
  https://doi.org/10.1186/s12885-022-09240-w
• Heinig M, Braitmaier M, Haug U. Prescribing of menopausal hormone therapy in Germany: Current status and changes between 2004 and 2016. Pharmacoepidemiology and Drug Safety. 2021;30(4):462-471.
  https://doi.org/10.1002/pds.5186
• Heinig M, Schwarz S, Haug U. Self-selection for mammography screening according to use of hormone replacement therapy: A systematic literature review. Cancer Epidemiology. 2021;71(Part A):101812.
  https://doi.org/10.1016/j.canep.2020.101812
  https://repository.publisso.de/resource/frl:6425860
• Schwarz S, Oppelt KA, Heinig M, Haug U. Potential of German claims data to characterize utilization of new cancer drugs: The example of crizotinib. Future Oncology. 2021;17(18):2305-2313.
  https://doi.org/10.2217/fon-2020-1052
  https://repository.publisso.de/resource/frl:6428548

• Poster bei wissenschaftlichen Tagungen

• Heinig M, Haug U. Long-term non-participants in cervical cancer screening in Germany: Preventive and other contacts with the health care system. Aarhus, Denmark. 2025.
• Heinig M, Haug U. German mammography screening program: Adherence, characteristics of (non-)participants and utilization of non-screening mammography - A longitudinal analysis. Turin, Italy. 2023.
• Garcia de Albeniz X, Riera Guardia N, Gutierrez L, Bahmanyar S, Blin P, Droz-Perroteau C, Heinig M, Linder M, Moore N, Schulze-Rath R, Sultana J, Trifirò G, Zhang W, Zong J. Feasibility of studying the use of tissue-agnostic cancer drugs in population-based European health databases. online poster. 2020.
• Heinig M, Haug U. The potential of claims data for long-term follow-up of breast cancer patients in Germany. Berlin. 2020.
• Heinig M, Haug U. Changes in prescribing of hormone replacement therapy in Germany between 2004 and 2016. online poster. 2020.

• Weitere Publikationen